Oncolytic polio virotherapy of cancer

Michael C. Brown, Elena Y. Dobrikova, Mikhail I. Dobrikov, Ross W. Walton, Sarah L. Gemberling, Smita K. Nair, Annick Desjardins, John H. Sampson, Henry S. Friedman, Allan H. Friedman, Douglas Tyler, Darell D. Bigner, Matthias Gromeier

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Recently, the century-old idea of targeting cancer with viruses (oncolytic viruses) has come of age, and promise has been documented in early stage and several late-stage clinical trials in a variety of cancers. Although originally prized for their direct tumor cytotoxicity (oncolytic virotherapy), recently, the proinflammatory and immunogenic effects of viral tumor infection (oncolytic immunotherapy) have come into focus. Indeed, a capacity for eliciting broad, sustained antineoplastic effects stemming from combined direct viral cytotoxicity, innate antiviral activation, stromal proinflammatory stimulation, and recruitment of adaptive immune effector responses is the greatest asset of oncolytic viruses. However, it also is the source for enormous mechanistic complexity that must be considered for successful clinical translation. Because of fundamentally different relationships with their hosts (malignant or not), diverse replication strategies, and distinct modes of tumor cytotoxicity/killing, oncolytic viruses should not be referred to collectively. These agents must be evaluated based on their individual merits. In this review, the authors highlight key mechanistic principles of cancer treatment with the polio:rhinovirus chimera PVSRIPO and their implications for oncolytic immunotherapy in the clinic.

Original languageEnglish (US)
Pages (from-to)3277-3286
Number of pages10
JournalCancer
Volume120
Issue number21
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Oncolytic Virotherapy
Poliomyelitis
Oncolytic Viruses
Neoplasms
Immunotherapy
Rhinovirus
Adaptive Immunity
Virus Diseases
Antineoplastic Agents
Antiviral Agents
Clinical Trials
Viruses

Keywords

  • CD155
  • eIF4G
  • innate antiviral response
  • interferon
  • internal ribosomal entry site
  • nectin-like molecule 5
  • oncolytic virus
  • poliovirus
  • translation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Brown, M. C., Dobrikova, E. Y., Dobrikov, M. I., Walton, R. W., Gemberling, S. L., Nair, S. K., ... Gromeier, M. (2014). Oncolytic polio virotherapy of cancer. Cancer, 120(21), 3277-3286. https://doi.org/10.1002/cncr.28862

Oncolytic polio virotherapy of cancer. / Brown, Michael C.; Dobrikova, Elena Y.; Dobrikov, Mikhail I.; Walton, Ross W.; Gemberling, Sarah L.; Nair, Smita K.; Desjardins, Annick; Sampson, John H.; Friedman, Henry S.; Friedman, Allan H.; Tyler, Douglas; Bigner, Darell D.; Gromeier, Matthias.

In: Cancer, Vol. 120, No. 21, 01.11.2014, p. 3277-3286.

Research output: Contribution to journalArticle

Brown, MC, Dobrikova, EY, Dobrikov, MI, Walton, RW, Gemberling, SL, Nair, SK, Desjardins, A, Sampson, JH, Friedman, HS, Friedman, AH, Tyler, D, Bigner, DD & Gromeier, M 2014, 'Oncolytic polio virotherapy of cancer', Cancer, vol. 120, no. 21, pp. 3277-3286. https://doi.org/10.1002/cncr.28862
Brown MC, Dobrikova EY, Dobrikov MI, Walton RW, Gemberling SL, Nair SK et al. Oncolytic polio virotherapy of cancer. Cancer. 2014 Nov 1;120(21):3277-3286. https://doi.org/10.1002/cncr.28862
Brown, Michael C. ; Dobrikova, Elena Y. ; Dobrikov, Mikhail I. ; Walton, Ross W. ; Gemberling, Sarah L. ; Nair, Smita K. ; Desjardins, Annick ; Sampson, John H. ; Friedman, Henry S. ; Friedman, Allan H. ; Tyler, Douglas ; Bigner, Darell D. ; Gromeier, Matthias. / Oncolytic polio virotherapy of cancer. In: Cancer. 2014 ; Vol. 120, No. 21. pp. 3277-3286.
@article{3b5c4912637343df8bdd9aadc81c46f5,
title = "Oncolytic polio virotherapy of cancer",
abstract = "Recently, the century-old idea of targeting cancer with viruses (oncolytic viruses) has come of age, and promise has been documented in early stage and several late-stage clinical trials in a variety of cancers. Although originally prized for their direct tumor cytotoxicity (oncolytic virotherapy), recently, the proinflammatory and immunogenic effects of viral tumor infection (oncolytic immunotherapy) have come into focus. Indeed, a capacity for eliciting broad, sustained antineoplastic effects stemming from combined direct viral cytotoxicity, innate antiviral activation, stromal proinflammatory stimulation, and recruitment of adaptive immune effector responses is the greatest asset of oncolytic viruses. However, it also is the source for enormous mechanistic complexity that must be considered for successful clinical translation. Because of fundamentally different relationships with their hosts (malignant or not), diverse replication strategies, and distinct modes of tumor cytotoxicity/killing, oncolytic viruses should not be referred to collectively. These agents must be evaluated based on their individual merits. In this review, the authors highlight key mechanistic principles of cancer treatment with the polio:rhinovirus chimera PVSRIPO and their implications for oncolytic immunotherapy in the clinic.",
keywords = "CD155, eIF4G, innate antiviral response, interferon, internal ribosomal entry site, nectin-like molecule 5, oncolytic virus, poliovirus, translation",
author = "Brown, {Michael C.} and Dobrikova, {Elena Y.} and Dobrikov, {Mikhail I.} and Walton, {Ross W.} and Gemberling, {Sarah L.} and Nair, {Smita K.} and Annick Desjardins and Sampson, {John H.} and Friedman, {Henry S.} and Friedman, {Allan H.} and Douglas Tyler and Bigner, {Darell D.} and Matthias Gromeier",
year = "2014",
month = "11",
day = "1",
doi = "10.1002/cncr.28862",
language = "English (US)",
volume = "120",
pages = "3277--3286",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "21",

}

TY - JOUR

T1 - Oncolytic polio virotherapy of cancer

AU - Brown, Michael C.

AU - Dobrikova, Elena Y.

AU - Dobrikov, Mikhail I.

AU - Walton, Ross W.

AU - Gemberling, Sarah L.

AU - Nair, Smita K.

AU - Desjardins, Annick

AU - Sampson, John H.

AU - Friedman, Henry S.

AU - Friedman, Allan H.

AU - Tyler, Douglas

AU - Bigner, Darell D.

AU - Gromeier, Matthias

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Recently, the century-old idea of targeting cancer with viruses (oncolytic viruses) has come of age, and promise has been documented in early stage and several late-stage clinical trials in a variety of cancers. Although originally prized for their direct tumor cytotoxicity (oncolytic virotherapy), recently, the proinflammatory and immunogenic effects of viral tumor infection (oncolytic immunotherapy) have come into focus. Indeed, a capacity for eliciting broad, sustained antineoplastic effects stemming from combined direct viral cytotoxicity, innate antiviral activation, stromal proinflammatory stimulation, and recruitment of adaptive immune effector responses is the greatest asset of oncolytic viruses. However, it also is the source for enormous mechanistic complexity that must be considered for successful clinical translation. Because of fundamentally different relationships with their hosts (malignant or not), diverse replication strategies, and distinct modes of tumor cytotoxicity/killing, oncolytic viruses should not be referred to collectively. These agents must be evaluated based on their individual merits. In this review, the authors highlight key mechanistic principles of cancer treatment with the polio:rhinovirus chimera PVSRIPO and their implications for oncolytic immunotherapy in the clinic.

AB - Recently, the century-old idea of targeting cancer with viruses (oncolytic viruses) has come of age, and promise has been documented in early stage and several late-stage clinical trials in a variety of cancers. Although originally prized for their direct tumor cytotoxicity (oncolytic virotherapy), recently, the proinflammatory and immunogenic effects of viral tumor infection (oncolytic immunotherapy) have come into focus. Indeed, a capacity for eliciting broad, sustained antineoplastic effects stemming from combined direct viral cytotoxicity, innate antiviral activation, stromal proinflammatory stimulation, and recruitment of adaptive immune effector responses is the greatest asset of oncolytic viruses. However, it also is the source for enormous mechanistic complexity that must be considered for successful clinical translation. Because of fundamentally different relationships with their hosts (malignant or not), diverse replication strategies, and distinct modes of tumor cytotoxicity/killing, oncolytic viruses should not be referred to collectively. These agents must be evaluated based on their individual merits. In this review, the authors highlight key mechanistic principles of cancer treatment with the polio:rhinovirus chimera PVSRIPO and their implications for oncolytic immunotherapy in the clinic.

KW - CD155

KW - eIF4G

KW - innate antiviral response

KW - interferon

KW - internal ribosomal entry site

KW - nectin-like molecule 5

KW - oncolytic virus

KW - poliovirus

KW - translation

UR - http://www.scopus.com/inward/record.url?scp=84925020556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925020556&partnerID=8YFLogxK

U2 - 10.1002/cncr.28862

DO - 10.1002/cncr.28862

M3 - Article

VL - 120

SP - 3277

EP - 3286

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 21

ER -